Académique Documents
Professionnel Documents
Culture Documents
It is composed of a
combination of factors from
the Virchow’s triad.
It is located in the Venous
sinusoids of muscles and
valves in veins.
It is composed of mainly
fibrin.
It is utilized for the purpose
of treating anticoagulants.
THE PRACTICAL ESSENTIALS
Ambrosino, P., Tarantino, L., Di Minno, G., Paternoster, M., Graziano, V., Petitto, M., ... & Di
Minno, M. N. D. (2017). The risk of venous thromboembolism in patients with
cirrhosis. Thrombosis and haemostasis, 26(01), 139-148.
Ay, C., Pabinger, I., & Cohen, A. T. (2017). Cancer-associated venous thromboembolism: burden,
mechanisms, and management. Thrombosis and haemostasis, 117(02), 219-230.
Cohen, A. T., Katholing, A., Rietbrock, S., Bamber, L., & Martinez, C. (2017). Epidemiology of
first and recurrent venous thromboembolism in patients with active cancer. Thrombosis and
haemostasis, 26(01), 57-65.
Connors, J. M. (2017). Thrombophilia testing and venous thrombosis. New England Journal of
Medicine, 377(12), 1177-1187.
Fang, M. C., Fan, D., Sung, S. H., Witt, D. M., Schmelzer, J. R., Steinhubl, S. R., ... & Go, A. S.
(2017). Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute
Venous Thromboembolism: The CVRN VTE Study. Medical care, 55(12), e137-e143.
Ferroni, P., Zanzotto, F. M., Scarpato, N., Riondino, S., Nanni, U., Roselli, M., & Guadagni, F.
(2017). Risk assessment for venous thromboembolism in chemotherapy-treated ambulatory
cancer patients: a machine learning approach. Medical Decision Making, 37(2), 234-242.
Gibson, C. M., Halaby, R., Korjian, S., Daaboul, Y., Arbetter, D. F., Yee, M. K., ... & Bandman,
O. (2017). The safety and efficacy of full-versus reduced-dose betrixaban in the Acute
Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration
Betrixaban (APEX) trial. American heart journal, 185, 93-100.
References
Heit, J. A., Ashrani, A. A., Crusan, D. J., McBane, R. D., Petterson, T. M., & Bailey, K. R.
(2017). Reasons for the persistent incidence of venous thromboembolism. Thrombosis
and haemostasis, 117(02), 390-400.
Khorana, A. A., Francis, C. W., Kuderer, N. M., Carrier, M., Ortel, T. L., Wun, T., ... &
Baran, A. (2017). Dalteparin thromboprophylaxis in cancer patients at high risk for
venous thromboembolism: a randomized trial. Thrombosis research, 151, 89-95.
Laliberté, F., Dea, K., Duh, M. S., Kahler, K. H., Rolli, M., & Lefebvre, P. (2018). Does the
route of administration for estrogen hormone therapy impact the risk of venous
thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone
therapy. Menopause, 25(11), 1297-1305.
Raskob, G. E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., ... & Meyer,
G. (2018). Edoxaban for the treatment of cancer-associated venous
thromboembolism. New England Journal of Medicine, 378(7), 615-624.
Trujillo-Santos, J., Di Micco, P., Dentali, F., Douketis, J., Díaz-Peromingo, J. A., Núñez, M.
J., ... & RIETE Investigators. (2017). Real-life treatment of venous thromboembolism
with direct oral anticoagulants: the influence of recommended dosing and
regimens. Thrombosis and haemostasis, 117(02), 382-389.
Van Es, N., Franke, V. F., Middeldorp, S., Wilmink, J. W., & Büller, H. R. (2017). The
Khorana score for the prediction of venous thromboembolism in patients with
pancreatic cancer. Thrombosis research, 150, 30-32.
Young, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., ... &
MacCallum, P. (2018). Comparison of an oral factor Xa inhibitor with low molecular
weight heparin in patients with cancer with venous thromboembolism: results of a
randomized trial (SELECT-D). Journal of Clinical Oncology, 36(20).
THANK YOU